Advancing Treatment Paradigms in Multiple Myeloma: The Impact and Innovation of Carvykti in the Landscape of Relapsed and Lenalidomide-Refractory Multiple Myeloma

Scheduled for:May 30, 2024 8:00 PM EDT

Call Duration:30 minutes

Desired Expert

An oncologist or hematologist specializing in multiple myeloma, with extensive experience in cellular therapies. The expert should have a robust background in clinical research, particularly in novel therapeutic agents and their application in hematologic malignancies. Familiarity with BCMA-targeted therapies and a deep understanding of multiple myeloma's pathophysiology are essential.

Interview Goal

This interview seeks to explore the transformative effects of Carvykti (ciltacabtagene autoleucel; cilta-cel) on the treatment of relapsed and lenalidomide-refractory multiple myeloma, focusing on its recently expanded FDA approval. We aim to discuss the critical outcomes from the Phase 3 CARTITUDE-4 study, its unique mechanism of action as a BCMA-targeted therapy, and what these findings mean for future therapeutic strategies. Additionally, the interview will consider the broader implications for patient management and the potential shift in treatment paradigms.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.